Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.

Molecular cancer therapeutics - 1 Feb 2005

Chen Allan Y, Shih Shyh-Jen, Garriques Liza N, Rothenberg Mace L, Hsiao Michael, Curran Dennis P

Abstract excerpt

The silatecan 7-tert-butyldimethylsilyl-10-hydroxy-camptothecin (DB-67) represents a new generation of camptothecin derivatives that exhibits a potent in vitro DNA topoisomerase I (TOP1)-mediated DNA-damaging activity, improved blood stability, and holds significant promise for the treatment of human cancers. In this study, we characterize the role of TOP1 in mediating the radiosensitization activity of DB-67. As...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to DNA Topoisomerases, Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type II

Share to Enzyme Inhibitors

Share to Glioma

Share to Radiation-Sensitizing Agents

Share to Radiation Tolerance

Share to Topoisomerase I Inhibitors

Source

Identifiers

PMID: 15713902

Genes

TOP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.PMID 15713902Read ↗

Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.Semantic proximity Read ↗

Targeting Topoisomerase I in the Era of Precision MedicineSemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damageSemantic proximity Read ↗

Identification and Biological Evaluation of a Novel and Potent Small Molecule Radiation Sensitizer via an Unbiased Screen of a Chemical LibrarySemantic proximity Read ↗

Identification of a Putative Tdp1 Inhibitor (CD00509) by in Vitro and Cell-Based AssaysSemantic proximity Read ↗

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical ModelsSemantic proximity Read ↗

4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.Semantic proximity Read ↗

Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycinSemantic proximity Read ↗

Novel camptothecin derivatives as topoisomerase I inhibitorsSemantic proximity Read ↗

Current Status and Perspectives in the Development of CamptothecinsSemantic proximity Read ↗

Small-Molecule Drugs Mimicking DNA Damage: A New Strategy for Sensitizing Tumors to RadiotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.